Cargando…

Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR

The epidermal growth factor receptor (EGFR) is a therapeutic target (oncotarget) in NSCLC. Using in vitro EGFR kinase activity system, we identified a novel small molecule, WB-308, as an inhibitor of EGFR. WB-308 decreased NSCLC cell proliferation and colony formation, by causing G2/M arrest and apo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jinsong, Deng, Huayun, Hu, Meichun, Fang, Yuanzhang, Vaughn, Amanda, Cai, Xiaopan, Xu, Leqin, Wan, Wei, Li, Zhenxi, Chen, Shijie, Yang, Xinghai, Wu, Song, Xiao, Jianru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466647/ https://www.ncbi.nlm.nih.gov/pubmed/25730907

Ejemplares similares

In vivo selection for spine-derived highly metastatic lung cancer cells is associated with increased migration, inflammation and decreased adhesion
por: Cai, Xiaopan, et al.
Publicado: (2015)

Surgical management and outcome of spinal alveolar soft part sarcoma (ASPA): a case series of five patients and literature review
por: Zhao, Chenglong, et al.
Publicado: (2017)

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
por: Zhu, Jing, et al.
Publicado: (2021)

Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)
por: Makhov, Petr, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
por: Qin, Qiong, et al.
Publicado: (2020)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

Spine extra-osseous chordoma mimicking neurogenic tumors: report of three cases and review of the literatures
por: Yang, Jian, et al.
Publicado: (2016)

EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
por: Steuer, Conor E., et al.
Publicado: (2020)

Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
por: Singh, Charu
Publicado: (2014)

Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
por: Zhou, Yongchun, et al.
Publicado: (2017)

The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC)
por: Ramadhan, Hanan H, et al.
Publicado: (2021)

Massive Spondylectomy for Metastatic Spinal Cord Compression From Non–Small-Cell Lung Cancer With Local Failure After Radiotherapy
por: Xu, Wei, et al.
Publicado: (2020)

Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations
por: Li, Junzhe, et al.
Publicado: (2023)

Reversal of EGFR inhibitors’ resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer
por: He, Fei, et al.
Publicado: (2019)

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
por: Lin, Anqi, et al.
Publicado: (2019)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Surgical efficacy and survival prediction of patients with unspecified malignant bone tumors
por: He, Shaohui, et al.
Publicado: (2022)

Surgical treatment of upper cervical spine metastases: a retrospective study of 39 cases
por: Yang, Jian, et al.
Publicado: (2017)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
por: Ghiso, Elena, et al.
Publicado: (2017)

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth
por: Niu, Mengmeng, et al.
Publicado: (2021)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
por: Wang, Shuhang, et al.
Publicado: (2015)

EGFR-Driven Mutation in Non-Small-Cell Lung Cancer (NSCLC) Influences the Features and Outcome of Brain Metastases
por: Armocida, Daniele, et al.
Publicado: (2023)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

miR-215 suppresses proliferation and migration of non-small cell lung cancer cells
por: Cai, Xiaopan, et al.
Publicado: (2017)

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
por: Berardi, Rossana, et al.
Publicado: (2013)

Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
por: Sung, Mike R., et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
por: Lin, Liping, et al.
Publicado: (2018)

Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)
por: Zhu, Qianqian, et al.
Publicado: (2017)

Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients
por: Deng, Qinfang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b2j11vfeubqj1lmf886ibkaljh